Effect of daclizumab, tacrolimus and mycophenolate mofetil in racial minority first renal transplant recipients.
Ciancio
Gaetano
G
Department of Surgery, Division of Transplantation, University of Miami School of Medicine, Highland Professional Building, 5th Floor, 1801 NW 9th Avenue, Suite 517, Miami, FL 33136, USA. gciancio@med.miami.edu
Burke
G W
GW
Suzart
K
K
Roth
D
D
Kupin
W
W
Rosen
A
A
Gomez
C
C
Mattiazzi
A
A
Esquenazi
V
V
Miller
J
J
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D044383:Black People; D002102:Cadaver; D002423:Cause of Death; D000077561:Daclizumab; D005431:Florida; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006630:Hispanic or Latino; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D019520:Living Donors; D008875:Middle Aged; D008913:Minority Groups; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012189:Retrospective Studies; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D014019:Tissue Donors; D017211:Treatment Failure; D016896:Treatment Outcome; D044465:White People; D001741:Black or African American
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab; D009173:Mycophenolic Acid; D016559:Tacrolimus